Q4 & FY 2015 RESULTS

February 25, 2016

Forenote
Cytec has not contributed to the 2015 Group income or cash flow statements, as its results and cash flows for the period between 09/12/2015 (acquisition date) and 31/12/2015 are not material. However, in order to provide a framework reference going forward, this report includes unaudited pro forma financial data including Cytec, as if the acquisition had taken place on 01/01/2015.

Besides IFRS accounts, Solvay also presents Adjusted Income Statement performance indicators that exclude non-cash Purchase Price Allocation (PPA) accounting impacts related to the Rhodia acquisition.

From Q1 2016, the Group’s results will be presented on an IFRS and Underlying basis only. The current definition of REBITDA will equate to Underlying EBITDA going forward.
This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.
Overview

- Transformation acceleration & delivery
- Financial highlights
- Priorities and Outlook
TRANFORMATION
ACCELERATION & DELIVERY

2015

• Step-change in portfolio upgrade
• Strong excellence delivery
• Solid earnings growth
• Enhanced sustainability commitments

Dividend up
2015
A STEP-CHANGE IN OUR TRANSFORMATION

Much stronger portfolio

ACQUISITIONS

Rhodia
Chemlogics
Ryton
Eco Services
INOVYN (JV)

DIVESTITURES

2011
2012
2013
2014
2015

More global
More diversified
Higher sustainability
More innovative
More resilient

FURTHER UPGRADE TO COME FROM DIVESTITURES

FY 2015 results
25/02/2016
AN ENHANCED BUSINESS PROFILE
MORE DIVERSIFIED & MORE RESILIENT

Solvay pro forma 2015 (including Cytec)

Balanced regional profile

- North America: 27%
- Latin America: 10%
- Europe: 30%
- Asia/Pacific & RoW: 33%

Diversified & higher growth end-markets

- Consumer goods & Healthcare: 21%
- Industrial applications: 18%
- Electrical & Electronics: 6%
- Automotive & Aeronautics: 26%
- Energy & Environment: 8%
- Agro, Feed & Food: 10%
- Building & Construction: 11%

30,910 employees
53 countries
145 industrial sites
21 main R&I centers

FY 2015 results
25/02/2016
STRATEGICALLY COHERENT BUSINESS SEGMENTS DRIVING RESULTS

Solvay pro forma 2015 (including Cytec)

**Net Sales**
€ 12.4 bn

**REBITDA**
€ 2,336 m

**REBITDA margin**
19%

**FCF**
€ 492 m

**Capex**
€ 1,092 m

**CFROI**
6.1%

**GROWTH ENGINES**

**ADVANCED MATERIALS**
High performance materials, providing solutions for sustainable mobility: light-weighting, CO₂ and energy efficiency

**ADVANCED FORMULATIONS**
Customized specialty formulations in surface chemistry, optimizing efficiency, minimizing environmental impact

**PERFORMANCE CHEMICALS**
Leading positions in chemical intermediates, through scale and technology

**FUNCTIONAL POLYMERS**
Leading regional positions in functional polymers, with focus on excellence

**Market positions:** ▼ Global market position in main markets addressed ▼ Regional market position in main markets addressed

FY 2015 results 25/02/2016
Solvay’s unique portfolio

BROADEST HIGH-PERFORMANCE POLYMER RANGE

- Thermoplastic polymers & alloys
- Thermoset resins & formulations
- Fiber reinforced compounds (short & long fiber)
- Composites thermoset & thermoplastics
- Sandwich structures

Creating New Classes of Materials

Providing Solutions For
- Lightweight materials for transportation
- Production cycle time acceleration
- Total cost reduction

Driving sustainable mobility

Automotive
- Under the hood
- Battery tray
- Upperbody/hood
- Chassis

Aerospace
- Primary structure
- Secondary structure
- Jet engines
- Cabin interior

Most Major OEMs Worldwide

Supported by regulatory framework for cleaner vehicles (aeronautics in discussion)

FY 2015 results
25/02/2016
BROAD OFFERING OF INNOVATIVE FORMULATIONS MODIFYING SURFACE CHEMISTRY & FLUID BEHAVIORS

COMPETITIVE technology portfolio

- Leader in global markets & niche specialty technologies:
  - MILD SURFACTANTS
  - NATURAL (GUAR) & SYNTHETIC POLYMERS
  - PHOSPHINES

- Supplying OEMs, Tier 1 B2B and global B2C brand-owners
- Highly competitive global on-pipe alkoxylation footprint

REDUCED environmental impact

ENHANCED EFFICIENCY FERTILIZERS

IMPROVED RECOVERY AND YIELD

COST EFFICIENT FRICITION REDUCERS

USING CUSTOMER INTIMACY & MARKET FOCUS AS CRITICAL SUCCESS FACTORS
EXCELLENCE SCOPE EXPANDED
STRONG DELIVERY

3-year excellence targets ...

Operational
€ 400 m
~80% achieved

Innovation
€ 270 m
~70% achieved

Commercial
€ 130 m
~80% achieved

... by YE 2015

> € 600m delivered in 2 years
on track to deliver € 800 m by 2016

Expected impact on 2016 REBITDA (vs 2013 base), excluding Cytec

FAST DELIVERY, MORE POTENTIAL
STRENGTHENED SUSTAINABILITY COMMITMENTS

SOLVAY
Contribute to Society

Innovate
Sustainable solutions
- Lightness
- Sustainable energy
- Ecofriendly materials
- Air and water care
- Smart and efficient processes

Act
Responsibly
- Operating responsibly
- Empowering people

SOCIETAL ACTIONS

x2
Employees involved in societal actions

SPM
50%
Share of sustainable solutions in the Group portfolio

PEOPLE MANAGEMENT
80%
Employee engagement index

CO₂
-40%
Reduction of carbon intensity

SAFETY
-50%
Of occupational accidents with MTAR target < 0.50

SOLVAY’S COMMITMENT BY 2025

FY 2015 results
25/02/2016
Overview

• Transformation acceleration & delivery
• Financial highlights
• Priorities and Outlook
## SOLID PERFORMANCE IN 2015 ON FINANCIAL & SUSTAINABILITY LEVEL

### Solvay stand-alone

| **REBITDA** | € m | 1,955 | ↑ 9.6% |
| **Net income** | € m | 477 | 156 in 2014 |
| **FCF** | € m | 387 | 656 in 2014 |
| **CFROI** | % | 6.9 | ➔ |
| **Dividend** | € / share | 3.3 | ↑ 3.3% |
| **Safety** | MTAR | 0.77 | (20)% |
| **GHG** | kg CO₂ / € | 7.26 | (10)% |
| **SPM** | Sustainable Portfolio Management | 33% Sustainable solutions | [✓] 8pp |
| **Employee engagement index** | % | 75 | [✓] |
| **Employees involved in societal actions** | % | 10 | [✓] |

### FY 2015 results

- **Net sales**: € 10.6 billion
- **Capex**: € 969 million
- **R&D**: New sales ratio<sup>[1]</sup>
- **Employees**: 26,350
- **Footprint**: > 50 countries

<sup>[1]</sup> New sales ratio = sales from products developed or improved in last 5 years

<sup>[2]</sup> MTAR = Medical Treatment Accident Rate

<sup>[3]</sup> CFROI = \( \frac{\text{REBITDA} - \text{capex - tax}}{\text{Gross assets + working capital}} \) with Gross assets at replacement value including goodwill

---

2015 Solvay stand-alone figures (with evolution vs 2014)
FOREX IMPACT ON SALES MORE THAN OFFSET MAJOR ADJUSTMENTS IN OIL & GAS AND ACETATE TOW MARKETS

Net Sales FY 2015
Solvay stand-alone
in € m

10,213
29
655
260
59
10,578

6% Conversion
3% Volume
1% Price

FY 2014
FY 2015

Supportive forex: USD mainly
- 2014: 1.33 $/€
- 2015: 1.11 $/€

Volumes down as contraction in acetate tow and oil & gas markets offset innovation driven-demand
- Advanced Formulations
- Advanced Materials
- Performance Chemicals
- Functional polymers

Pricing stable despite lower raw material prices
INNOVATION, EXCELLENCE & FOREX SUPPORT REBITDA GROWTH DESPITE SOME MAJOR MARKET HEADWINDS

REBITDA FY 2015
Solvay stand-alone
in € m

1,783

163

(1)

Conversion
forex
9%

(147)

Volume
(8)%

246

(59)

Price
(3)%

18

Variable
costs
14%

9.6%

Pricing power
€ 187 M

1,955

Supportive forex
USD mainly

Pricing power
across segments
underpinned by
Excellence

Fixed costs up
8 new plants
commissioned

Excellence offset
inflation

FY 2014
17% margin

1.0pp

FY 2015
18% margin

OVERALL
EXCELLENCE
MEASURES EXCEED
€ 300 M
NET INCOME REFLECTING PORTFOLIO UPGRADE EXCEPTIONALS UNDERLYING NET INCOME UP 9%

### P&L Solvay stand-alone

<table>
<thead>
<tr>
<th></th>
<th>Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY 2015</td>
</tr>
<tr>
<td>Net sales</td>
<td>10,578</td>
</tr>
<tr>
<td>REBITDA</td>
<td>1,955</td>
</tr>
<tr>
<td>Depreciation &amp; Amortization</td>
<td>(733)</td>
</tr>
<tr>
<td>Other elements</td>
<td>(35)</td>
</tr>
<tr>
<td>Non-recurring items</td>
<td>(245)</td>
</tr>
<tr>
<td><strong>EBIT</strong></td>
<td>941</td>
</tr>
<tr>
<td>Net financial charges</td>
<td>(226)</td>
</tr>
<tr>
<td>Income taxes</td>
<td>(135)</td>
</tr>
<tr>
<td><strong>Result continuing operations</strong></td>
<td>580</td>
</tr>
<tr>
<td>Result discontinued operations</td>
<td>(55)</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>525</td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>(48)</td>
</tr>
<tr>
<td><strong>Net income Solvay share</strong></td>
<td>477</td>
</tr>
<tr>
<td>Underlying</td>
<td>680</td>
</tr>
</tbody>
</table>

**Adjusted:** Excluding non-cash PPA accounting impacts related to the Rhodia acquisition  
**Underlying:** Excluding non-cash PPA and other exceptional, as well as reclassifying hybrid bonds dividends as financial charges

### Non-recurring costs
- € (130) m related to Cytec acquisition
- Restructuring expenses and impairments, environmental provisions

### Net financial charges
- lower due to discount rate changes
  - Net debt charges stable
  - Lower discounting costs for pension and environmental provisions due to higher discount rates

### Income taxes
- up with higher results
  - € 107 m exceptional impact (e.g. recognition of deferred tax assets)
  - Underlying tax rate of 30%, vs 35% in 2014

### Discontinued operations
- result up due to important impairments in chlorovinyls
  - LatAm Indupa in 2015;
  - European Chlorovinyls in 2014 (partly offset by capital gain on sale of Eco Services)
# COMBINED ENTITY PRO FORMA 2015

PROVIDING ROBUST BASE FOR GROWTH

## P&L 2015 pro forma (Solvay + Cytec)

<table>
<thead>
<tr>
<th></th>
<th>Solvay stand-alone</th>
<th>Cytec stand-alone</th>
<th>Funding Cytec</th>
<th>IFRS</th>
<th>Adjustments [1]</th>
<th>Underlying</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>10,578</td>
<td>1,800</td>
<td></td>
<td>12,378</td>
<td>-</td>
<td>12,378</td>
</tr>
<tr>
<td><strong>REBITDA</strong></td>
<td><strong>1,955</strong></td>
<td><strong>381</strong></td>
<td></td>
<td><strong>2,336</strong></td>
<td>-</td>
<td><strong>2,336</strong></td>
</tr>
<tr>
<td>Depreciation &amp; Amortization</td>
<td>(842)</td>
<td>(311)</td>
<td></td>
<td>(1,153)</td>
<td>367</td>
<td>(786)</td>
</tr>
<tr>
<td>Other elements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35</td>
<td>-</td>
</tr>
<tr>
<td>Non-recurring items</td>
<td>(245)</td>
<td>(11)</td>
<td></td>
<td>(256)</td>
<td>256</td>
<td>-</td>
</tr>
<tr>
<td><strong>EBIT</strong></td>
<td>833</td>
<td>59</td>
<td></td>
<td>892</td>
<td>658</td>
<td>1,550</td>
</tr>
<tr>
<td>Net financial charges</td>
<td>(226)</td>
<td>(32)</td>
<td>(66)</td>
<td>(324)</td>
<td>(120)</td>
<td>(444)</td>
</tr>
<tr>
<td>Income taxes</td>
<td>(97)</td>
<td>(3)</td>
<td>37</td>
<td>(63)</td>
<td>(268)</td>
<td>(331)</td>
</tr>
<tr>
<td><strong>Tax rate</strong></td>
<td>17%</td>
<td>12%</td>
<td></td>
<td>12%</td>
<td>-</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Result from continuing operations</strong></td>
<td><strong>509</strong></td>
<td><strong>24</strong></td>
<td><strong>(29)</strong></td>
<td><strong>504</strong></td>
<td>270</td>
<td><strong>774</strong></td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>454</td>
<td>23</td>
<td>(29)</td>
<td>448</td>
<td>385</td>
<td><strong>833</strong></td>
</tr>
<tr>
<td>Non-controlling interests</td>
<td>(48)</td>
<td>-</td>
<td>-</td>
<td>(48)</td>
<td>(17)</td>
<td>(65)</td>
</tr>
<tr>
<td><strong>Net income Solvay share</strong></td>
<td><strong>406</strong></td>
<td><strong>23</strong></td>
<td><strong>(29)</strong></td>
<td><strong>400</strong></td>
<td>368</td>
<td><strong>768</strong></td>
</tr>
<tr>
<td>Basic EPS from continuing operations (in €)</td>
<td>5.57</td>
<td></td>
<td></td>
<td>4.45</td>
<td>2.53</td>
<td>6.98</td>
</tr>
<tr>
<td>Basic EPS (in €)</td>
<td>4.85</td>
<td></td>
<td></td>
<td>3.85</td>
<td>3.54</td>
<td>7.40</td>
</tr>
<tr>
<td><strong>CFROI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>6.1%</strong></td>
<td></td>
</tr>
</tbody>
</table>

[1] PPA and other adjustments

FY 2015 results
25/02/2016
CYTEC DELIVERING ON EARNINGS GROWTH TARGETS DRIVEN BY ADVANCED TECHNOLOGY & IMPROVED PRODUCTIVITY

Represented according to US GAAP in USD excluding one-off items and Corporate & unallocated costs

<table>
<thead>
<tr>
<th>Cytec (in USS)</th>
<th>Net sales</th>
<th>Operating earnings</th>
<th>Operating margins</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY 2015</td>
<td>FY 2014</td>
<td>% vov</td>
</tr>
<tr>
<td>Aerospace Materials</td>
<td>1,028</td>
<td>1,000</td>
<td>3%</td>
</tr>
<tr>
<td>Industrial Materials</td>
<td>268</td>
<td>326</td>
<td>(18)%</td>
</tr>
<tr>
<td>In Process Separation</td>
<td>432</td>
<td>411</td>
<td>5%</td>
</tr>
<tr>
<td>Additive Technologies</td>
<td>268</td>
<td>271</td>
<td>(1)%</td>
</tr>
<tr>
<td>Total</td>
<td>1,996</td>
<td>2,008</td>
<td>(1)%</td>
</tr>
</tbody>
</table>

Strong performance of **Aerospace Materials** and **In Process Separation**, with increased margins

→ Productivity improvements in Aerospace Materials
→ Favorable product mix in In Process Separation
→ Lower raw material costs

Weaker performance at **Industrial Materials** after strong 2014

→ Demand impacted by softer market conditions across greater Europe
→ Challenges from new ERP start-up
PEAK GROWTH INVESTMENTS IN 2015 ...

<table>
<thead>
<tr>
<th>Capex</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solvay stand-alone</td>
<td>734</td>
<td>861</td>
<td>969</td>
</tr>
<tr>
<td>Continuing operations</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Growth capex**
- **Maintenance capex**

→ 2015

- 8 new facilities commissioned
- HPPO Saudi Arabia → ~9 month delay

### Growth projects[^1]

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advanced Formulations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty surfactant plant in Germany</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkoxylation plant in U.S.</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Alkoxylation plant in Singapore</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanillin plant in China</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Fluoropolymers plant in China: phase 1 / phase 2</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Advanced Materials</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoropolymers plant in China: phase 1 / phase 2</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>PEEK exp. India</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEEK plant in USA</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silica plant in Poland</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silica plant in Korea</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td><strong>Performance Chemicals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bicarbonate plant in Thailand</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soda ash expansion in U.S.</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPPO plant in Saudi Arabia</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>H₂O₂ plant in China</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

[^1]: Main growth projects only

FY 2015 results
25/02/2016
... TO REDUCE GOING FORWARD WITH INTENSIFIED FOCUS ON CASH GENERATION

Selective investments for future value creation

Cash conversion

\[
\text{REBITDA-capex} \div \text{REBITDA} \times 100 = \%
\]

- 2013: 54%
- 2014: 52%
- 2015: 50%
- 2015 PF: 53%

Capex

- Continuing operations in €m
  - Growth capex
  - Maintenance capex

- 2013: 734
- 2014: 861
- 2015: 969 (Cytec -113)
- 2015 PF: 1,092
- 2016e: ~950

→ 2016

Growth capex at ~60% of total with ~2/3rd in Advanced Materials

- Aerospace investments
- PEEK plant in US
- Fluoropolymer plant in China, phase 2
- HPPO plant in Saudi Arabia

Capex discipline to reduce capital intensity

- Strategic fit
- IRR ≥ 15%

Profit growth

Improved cash conversion

SUSTAINABLE IMPROVEMENT IN FREE CASH FLOW

FY 2015 results
25/02/2016
**SOUND CASH GENERATION**

**Underlying net debt**

**evolution**

in € m

<table>
<thead>
<tr>
<th>Date</th>
<th>REBITDA</th>
<th>Capex</th>
<th>Provisions &amp; other operating cash flow</th>
<th>Change in working capital</th>
<th>FCF of discontinued operations</th>
<th>Interest charges</th>
<th>Dividends to Solvay shareholders</th>
<th>Other changes in net debt</th>
<th>rights issue</th>
<th>Acquisition cost</th>
<th>Net debt</th>
<th>Cytel impact</th>
<th>IFRS</th>
<th>Hybrid bonds</th>
<th>Hybrid bonds</th>
</tr>
</thead>
<tbody>
<tr>
<td>31/12/2014</td>
<td>(1,972)</td>
<td></td>
<td>(969)</td>
<td>(546)</td>
<td>(49)</td>
<td></td>
<td></td>
<td></td>
<td>(1,477)</td>
<td>(5,631)</td>
<td>(5,099)</td>
<td>(532)</td>
<td>(4,379)</td>
<td>(778)</td>
<td>(2,188)</td>
</tr>
<tr>
<td>31/12/2015</td>
<td>1,955</td>
<td></td>
<td>(56)</td>
<td></td>
<td></td>
<td>(156)</td>
<td>(282)</td>
<td>(331)</td>
<td>(6,567)</td>
<td>(5,099)</td>
<td>(532)</td>
<td>(1,477)</td>
<td>(5,631)</td>
<td>(1,972)</td>
<td>(1,972)</td>
</tr>
</tbody>
</table>

**Strong Free cash flow**

- Thanks to REBITDA increase & IWC control
- Despite capex increase with cash conversion [2] of 50%

**Provisions & other OCF**

- Taxes of € (245) m
- Movements in provisions including € 119 m pensions (net of service costs)

**Other changes in net debt**

- M&A other than Cytel of € (208) m mainly taxes on Eco Services disposal in 2014
- Dividends to minorities of € (41) m

---

[1] Underlying net debt reclassifies hybrid perpetual bonds (considered as equity under IFRS) as debt
[2] (REBITDA – capex) / REBITDA

21 FY 2015 results 25/02/2016

SOLVAY asking more from chemistry®
INVESTMENT GRADE CREDIT RATINGS CONFIRMED

Underlying net debt\(^1\) evolution in € bn

<table>
<thead>
<tr>
<th>Date</th>
<th>Net debt (€ bn)</th>
<th>Gross debt (€ bn)</th>
<th>Cash &amp; cash equivalents</th>
<th>Other debt (€ bn)</th>
<th>EUR bonds (€ bn)</th>
<th>USD bonds (€ bn)</th>
<th>Hybrid bonds (€ bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30/09/2015</td>
<td>2.7</td>
<td>3.9</td>
<td></td>
<td>1.4</td>
<td>1.3</td>
<td>1.5</td>
<td>2.2</td>
</tr>
<tr>
<td>31/12/2015</td>
<td>6.6</td>
<td>8.7</td>
<td></td>
<td>1.5</td>
<td>3.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Net debt is the total amount of debt a company has, including both short-term and long-term debt. Gross debt is the total amount of debt a company has, including the effect of interest rate swaps. Cash & cash equivalents include cash on hand, cash in banks, and short-term investments. Other debt includes long-term debt, bonds, and other long-term obligations. EUR bonds are bonds issued in euros, USD bonds are bonds issued in US dollars, and Hybrid bonds are convertible bonds that can be exchanged for shares of the company.

Cytec financing: The difference between the net debt at the end of the year and the beginning of the year is due to new debt financing and the repayment of existing debt.

For upcoming refinancing: This indicates that the company is planning to refinance existing debt in the future.

Leverage\(^3\) = net debt / REBITDA
Gearing = net debt / equity

<table>
<thead>
<tr>
<th>Leverage</th>
<th>Gearing</th>
<th>Rating</th>
<th>Outlook</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.8x</td>
<td>88%</td>
<td>A1</td>
<td>Positive</td>
</tr>
<tr>
<td>1.9x</td>
<td>45%</td>
<td>A1</td>
<td>Positive</td>
</tr>
</tbody>
</table>

Moody's and S&P are two of the major credit rating agencies that assess the creditworthiness of a company. Moody's gives a Baa2 rating with a negative outlook, indicating that the company's creditworthiness is strong but could weaken in the near future. S&P gives a BBB- rating with a stable outlook, indicating that the company's creditworthiness is strong and stable.

FY 2015 results 25/02/2016

\(^1\) Underlying net debt reclassifies hybrid perpetual bonds (considered as equity under IFRS) as debt
\(^2\) including other major EUR debt
\(^3\) based on pro forma REBITDA
Overview

- Transformation acceleration & delivery
- Financial highlights
- Priorities and Outlook
FOCUS ON DELIVERY

2016 Priorities

- Cytec integration, synergies acceleration
- Volume growth
- Excellence initiatives
- Intensified focus on cash generation
- Continuing portfolio upgrade
RAPID & EFFECTIVE SYNERGY REALIZATION
TOTAL SYNERGIES EXPECTED WELL ABOVE ORIGINAL €100 M

Cost synergies:  > €100m by end of 2018
→ Corporate overhead and G&A: - €20 m already captured as of January 1, 2016
→ Supply chain & procurement
→ Excellence practices

Revenue synergies: Additional upside
→ Acceleration of lightweighting opportunities across Specialty Polymers & Composite Materials
→ Cross-selling opportunities with Advanced Formulations
→ More being identified

People synergies: Leveraging talent
→ Best practice emulation
→ Cross fertilization
DELIVERING GROWTH IN 2016

Volume growth
→ New Capacity available
→ Innovation
→ Debotlenecking

Cash generation
→ REBITDA growth
→ Lower capex
→ Improved cash conversion

ENABLED BY EXCELLENCE MEASURES
€ 800 M
(CUMULATIVE BY END 2016 VS 2013)

ADVANCED MATERIALS
→ Growth in diversified markets to overcome Q1 inventory destocking in smart devices
→ Continued growth from ramp-up of aircraft with higher composites content

ADVANCED FORMULATIONS
→ Growth in health, personal care, agro and Technology Solutions businesses...
→ ... to offset continuing oil & gas market weakness

PERFORMANCE CHEMICALS
→ New Bicarbonate plant in Thailand
→ Return to growth in acetate tow

FUNCTIONAL POLYMERS
→ Growth in Engineering Plastics’ downstream applications
OUTLOOK 2016

REBITDA to grow high single digits
Growth to be back-ended

Free cash flow to exceed €650 m
REWARDING SHAREHOLDERS

SOLVAY GROSS DIVIDEND 2015

<table>
<thead>
<tr>
<th>Interim dividend</th>
<th>€ 1.36 / share</th>
<th>Paid on January 21, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final dividend[1]</td>
<td>€ 1.94 / share</td>
<td>To be paid on May 17, 2016</td>
</tr>
<tr>
<td><strong>Total[1]</strong></td>
<td>€ 3.30 / share</td>
<td><strong>Up 3.3% [2]</strong></td>
</tr>
</tbody>
</table>

DELIVERY ON COMMITMENTS

Gross dividend [2] in €/share

<table>
<thead>
<tr>
<th>Year</th>
<th>Gross Dividend</th>
</tr>
</thead>
<tbody>
<tr>
<td>1982</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>1985</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>1988</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>1991</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>1994</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>1997</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>2000</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>2003</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>2006</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>2009</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>2012</td>
<td>€ 0.00</td>
</tr>
<tr>
<td>2015</td>
<td>€ 3.30</td>
</tr>
</tbody>
</table>

For >30 years | 5.7% DPS CAGR | ~40% average pay-out

Committed to stable / growing dividend

FY 2015 results
25/02/2016

[1] Recommended dividend, pending General Shareholders meeting
[2] Adjusted with 0.9398 factor following December 2015 rights issue
OUR COMMITMENT

Exceed expectations on Cytec synergies

Excellence & Portfolio optimization continuing

Intensified focus on cash generation

Attractive returns to shareholders
INVESTOR RELATIONS

Maria Alcón-Hidalgo
+32 2 264 1984
maria.alconhidalgo@solvay.com

Jodi Allen
+1 (973) 357 3283
jodi.allen@solvay.com

Geoffroy Raskin
+32 2 264 1540
geoffroy.raskin@solvay.com

Bisser Alexandrov
+32 2 264 3687
bisser.alexandrov@solvay.com

NEXT EVENTS

May 3
2016
Q1 2016 results

May 10
2016
Annual general meeting

May 17
2016
Final dividend payment
- ex-coupon date: 13/05
- record date: 16/05

July 29
2016
Q2 & H1 2016 results

November 8
2016
Q3 2016 results

FY 2015 results
25/02/2016
Appendix

• 2015 FY Solvay stand-alone segment information
• Additional 2015 FY financial data
• Solvay pro forma information
• Forex sensitivity & other financial considerations
STRONG REBITDA GROWTH IN 2015 IN 3 OUT OF 4 SEGMENTS

Innovation mitigating major O&G market adjustments

€ 1,955 m
Solvay stand-alone

Excellence-driven margin expansion

**ADVANCED FORMULATIONS**
- FY 2014: 426 (15% margin)
- FY 2015: 378 (14% margin)

**ADVANCED MATERIALS**
- FY 2014: 709 (26% margin)
- FY 2015: 836 (25% margin)

**FUNCTIONAL POLYMERS**
- FY 2014: 111 (6.7% margin)
- FY 2015: 141 (9.5% margin)

**PERFORMANCE CHEMICALS**
- FY 2014: 724 (25% margin)
- FY 2015: 789 (26% margin)
ADVANCED FORMULATIONS FY 2015 PERFORMANCE
OIL & GAS HEADWINDS OFFSET IMPROVEMENT OTHER MARKETS

Net sales (in € m)

<table>
<thead>
<tr>
<th>FY 2014</th>
<th>FY 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,854</td>
<td>2,652</td>
</tr>
<tr>
<td>(14%)</td>
<td>(7.1)%</td>
</tr>
</tbody>
</table>

- Scope (0.5)%
- Conversion forex (1,818)%
- Volume (145)%
- Price 19%

REBITDA (in € m)

<table>
<thead>
<tr>
<th>FY 2014</th>
<th>FY 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>426</td>
<td>378</td>
</tr>
<tr>
<td>(11)%</td>
<td></td>
</tr>
</tbody>
</table>

- 15% REBITDA margin
- 14%

Market contraction in Novecare’s oil & gas activities
- Sharp fall in unconventional North American oil & gas markets continuing
- Cementing, drilling and stimulation subsectors down; production subsector resilient though
- Innovation delivery, competitiveness actions mitigate price pressure and reduces fixed costs
- Good developments in agro, coatings and HPC

Coatis supported by forex
- Weak domestic demand in Latin America
- BRL weakness underpinned competitive position

Volume growth in Aroma Performance
- Strong volume growth in vanillin and hydroquinone inhibitors
- Strong industrial performance following production issues in 2014

FY 2015 results
25/02/2016
ADVANCED MATERIALS FY 2015 PERFORMANCE
INNOVATION-DRIVEN REBITDA RECORD

Net sales (in € m)

<table>
<thead>
<tr>
<th>FY 2014</th>
<th>FY 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,762</td>
<td>3,334</td>
</tr>
</tbody>
</table>

- Scope 4%
- Conversion forex 228%
- Volume 69%
- Price 15%

21% increase

REBITDA (in € m)

<table>
<thead>
<tr>
<th>FY 2014</th>
<th>FY 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>709</td>
<td>836</td>
</tr>
</tbody>
</table>

- REBITDA margin 26%
- 25%

Specialty Polymers’ growth driven by innovative products

- Higher volumes, supportive forex and pricing power led to another strong performance
- Demand in smart devices, automotive and other high-end applications was strong
- Only at year end a more moderate growth on sales phasing in smart devices was observed

Volume growth and good pricing at Silica

- Strong sales benefitted from price and volume increases
- Demand for energy-efficient tires in Europe and North America growing, whereas Asia’s macro context subdued
- New plant in Poland in qualification process

Good dynamics at Special Chem

- Good volume growth in rare earth compounds (mainly for automotive diesel catalysts), fluor specialties and electronic materials
- The new high-purity H2O2 units in the U.S. are ramping up

FY 2015 results
25/02/2016
PERFORMANCE CHEMICALS FY 2015 PERFORMANCE PRICING OFFSET DESTOCKING HEADWINDS IN ACETOW

**Net sales (in € m)**

- FY 2014: 2,944
- FY 2015: 3,090

- Scope: 5.0%
- Conversion forex: 4%
- Volume: (2)%
- Price: 3%

**REBITDA (in € m)**

- FY 2014: 724
- FY 2015: 789

- REBITDA margin: 8.9%
- REBITDA margin: 26%

---

**Strong pricing at Soda Ash & Derivatives**

- Successful pricing strategy in soda ash underpinned by ongoing excellence programs
- Overall sales volumes stable
- Bicarbonate sales up; New Thai plant ramping up since September

**Strong performance at Peroxides**

- Net pricing gains on higher average sales prices and energy prices
- Sales volumes stable
- HPPO mega plants at high capacity rates

**Destocking persists in Acetow’s market**

- Destocking in the acetate tow market persisted, although situation improved in H2'15
- Positive net pricing underpinned by forex

**Emerging Biochemicals up on volumes and forex**

- Good performance on favorable forex and excellence programs
- Higher volumes from PVC exports out of Thailand offset lower pricing
- Epicerol® volumes stable

---

FY 2015 results
25/02/2016

SOLVAY asking more from chemistry®
FUNCTIONAL POLYMERS FY 2015 PERFORMANCE
EXCELLENCE-DRIVEN PROFIT RESTORATION

Net sales (in € m)

<table>
<thead>
<tr>
<th>FY 2014</th>
<th>1,654</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope (5)%</td>
<td>24</td>
</tr>
<tr>
<td>Conversion forex 1%</td>
<td>2</td>
</tr>
<tr>
<td>Volume -</td>
<td>(111)</td>
</tr>
<tr>
<td>Price (7)%</td>
<td>(9.9)%</td>
</tr>
</tbody>
</table>

FY 2015 | 1,490 |

REBITDA (in € m)

<table>
<thead>
<tr>
<th>FY 2014</th>
<th>111</th>
</tr>
</thead>
<tbody>
<tr>
<td>REBITDA margin</td>
<td>6.7%</td>
</tr>
</tbody>
</table>

FY 2015 | 141 |
| REBITDA margin | 9.5% |

Operating performance well up in Polyamide

- Strong net pricing on excellence programs implemented in the PA6.6 upstream businesses, lower raw materials prices as well as positive transaction forex effects
- Volumes were flat overall
- Poor economic conditions persist in Brazil, Fibras’ home market

Chlorovinyls’ result up yoy

- The ramp-up of RusVinyl JV in Russia contributed positively to the operational result
- INOVYN contribution included since Q3, but only reflecting mark-to-market of exit fee
Contributed from Energy Services down

- Poor contribution of Energy Services € (3) m or € (28) m lower than in 2014
- Difficult conditions for investments in biomass-based energy plants as well as the energy and carbon management services in a low commodity price environment
- In Q3 2015 a € (7) m one-off impairment on outstanding carbon emission rights in Brazil was booked

Other Corporate & Business Services

- Better year on year performance linked to back-end loaded cost phasing in 2014 and continued excellence measures offsetting the adverse impact of exchange rates and inflation
- In Q1 2015 a one-off benefit of € 30 m linked to the evolution of the post-employment Medicare insurance policy in the U.S. was booked
WORKING CAPITAL DISCIPLINE MAINTAINED

Industrial working capital[1]
Solvay stand-alone
% of total sales

15.2% 15.6% 16.3% 12.8%
16.5% 15.7% 15.6% 14.0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2014 2015

→ Superior specialty businesses growth increased industrial working capital needs

Committed to further optimization

[1] Quarter end industrial working capital / annualized quarter total sales
Yearly number is average of the quarters
DEBT PROFILE
BALANCED MATURITIES ALLOWING FLEXIBILITY

<table>
<thead>
<tr>
<th></th>
<th>Face value</th>
<th>Average duration[1]</th>
<th>Average cost</th>
<th>Legend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing debt</td>
<td>2,500</td>
<td>3.1</td>
<td>5.0%</td>
<td>Existing EUR hybrid bonds (at 1st call date) including € 500 m 6.38% 2016 treated as debt</td>
</tr>
<tr>
<td>Cytec debt</td>
<td>673</td>
<td>7.4</td>
<td>4.3%</td>
<td>Cytec USD bonds</td>
</tr>
<tr>
<td>New debt</td>
<td>4,720</td>
<td>6.6</td>
<td>3.1%</td>
<td>New EUR hybrid bonds (at 1st call date)</td>
</tr>
<tr>
<td>Total major debt</td>
<td>7,892</td>
<td>5.6</td>
<td>3.8%</td>
<td>New USD bonds</td>
</tr>
</tbody>
</table>

in € m  in years

Pension Liabilities

Pensions (31/12/2015) in € bn

- Net pension liabilities (3.0)
  - Cytec addition: 0.8
  - Solvay stand-alone: 2.1

Cash contribution of € (168) m in 2015
- vs € (180) m in 2014

Pension assets of € 2.9 bn
- Up € 0.8 bn vs 30/09/14 mainly due to Cytec acquisition
- ~50% Equities / Diversified alternative funds
- ~50% Bonds / Real estate

Net pension liabilities up € 0.1 bn to € 3.0 bn
- € 206 m or 7.0% of total net liability is due to Cytec
- France, Germany and UK relative weight decreased while North America increased after Cytec acquisition.

Discount rates [1] increased in 2015

<table>
<thead>
<tr>
<th>Currency</th>
<th>31/12/2015</th>
<th>31/12/2014</th>
<th>Change</th>
<th>Average duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR</td>
<td>2.25%</td>
<td>1.75%</td>
<td>0.50pp</td>
<td>13.1 years</td>
</tr>
<tr>
<td>GBP</td>
<td>3.75%</td>
<td>3.50%</td>
<td>0.25pp</td>
<td>16.4 years</td>
</tr>
<tr>
<td>USD</td>
<td>4.25%</td>
<td>4.00%</td>
<td>0.25pp</td>
<td>11.6 years</td>
</tr>
<tr>
<td>Weighted average</td>
<td>3.30%</td>
<td>2.71%</td>
<td>0.59pp</td>
<td>13.7 years</td>
</tr>
</tbody>
</table>

[1] Average discount rate on post employment benefit related liabilities applicable to high quality corporate bonds in EUR, GBP and USD zones.

All presented figures are for continuing operations only.
### Solvay Realigned Business Segments Including Cytec Strategically Coherent to Drive Results

**2015 PF**
- **€ 2,336 m** REBITDA

**Market positions:**
- Global market position in main markets addressed
- Regional market position in main markets addressed

#### Growth Engines

<table>
<thead>
<tr>
<th>Materials</th>
<th><strong>Advanced Materials</strong></th>
<th><strong>Advanced Formulations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Specialty Polymers</td>
<td>#1</td>
<td>Novecare #1</td>
</tr>
<tr>
<td>Composite Materials</td>
<td>#2</td>
<td>Technology Solutions #1</td>
</tr>
<tr>
<td>Special Chem</td>
<td>#1</td>
<td>Aroma Performance #1</td>
</tr>
<tr>
<td>Silica</td>
<td>#1</td>
<td></td>
</tr>
</tbody>
</table>

#### Resilient Cash Contributor

<table>
<thead>
<tr>
<th>Chemicals</th>
<th><strong>Performance Chemicals</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Soda Ash &amp; Derivatives</td>
<td>#1</td>
</tr>
<tr>
<td>Peroxides</td>
<td>#1</td>
</tr>
<tr>
<td>Acetow</td>
<td>#4</td>
</tr>
<tr>
<td>Coatis</td>
<td>#1</td>
</tr>
</tbody>
</table>

#### Functional Polymers

<table>
<thead>
<tr>
<th>Polymers</th>
<th><strong>Polyamide</strong></th>
<th><strong>Chlorovinyls</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>#3</td>
<td>#2</td>
</tr>
</tbody>
</table>
FOREX IMPACTS

Forex sensitivity in 2016

- Immediate impact on conversion exposure
- Deferred transactional impact due to hedging (6-12 month rolling basis)
- Mainly linked to USD
  - Sensitivity in 2016: ~€ 130 m REBITDA per (0.10) $/€
  - Half conversion, half transactional
- Main other currencies exposed to
  - JPY, CNY, THB, BRL, KRW, RUB

Forex development in 2015

- Total conversion impact of € 168 m (~2/3rd from USD/EUR increase)
- Total transactional impact of € 70 m

Solvay’s main currencies through 2015

<table>
<thead>
<tr>
<th>/€</th>
<th>USD</th>
<th>JPY</th>
<th>RUB</th>
<th>BRL</th>
<th>CNY</th>
<th>KRW</th>
<th>THB</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2014</td>
<td>1.33</td>
<td>140.31</td>
<td>50.95</td>
<td>3.12</td>
<td>8.19</td>
<td>1.398</td>
<td>43.15</td>
</tr>
<tr>
<td>FY 2015</td>
<td>1.11</td>
<td>134.31</td>
<td>68.07</td>
<td>3.70</td>
<td>6.97</td>
<td>1.257</td>
<td>38.03</td>
</tr>
<tr>
<td>Change</td>
<td>-0.22</td>
<td>-5.99</td>
<td>17.12</td>
<td>0.58</td>
<td>-1.21</td>
<td>-142</td>
<td>-5.12</td>
</tr>
<tr>
<td>Change in %</td>
<td>-16%</td>
<td>-4%</td>
<td>34%</td>
<td>19%</td>
<td>-15%</td>
<td>-10%</td>
<td>-12%</td>
</tr>
</tbody>
</table>
# EBIT(DA) Considerations for 2016

## Excellence
- Excellence programs on course to reach target
  - €800 m cumulative benefits by end 2016 vs 2013 cost base
  - >€600 m delivered in 2014-2015
- Cytec synergies from integration by 2018
  - Cost savings estimated >€100 m
  - Revenue synergies on top

## Depreciation & amortization
- Underlying depreciation & amortization expected at ~€ (800) m (excluding PPA amortization)
- PPA amortization of ~€ (370) m, consisting of PA impacts from Rhodia, Cytec and other smaller acquisitions (Chemlogics, Ryton)

## Scope effects
- Acquisitions in 2015
  - Cytec full consolidation as of January 1 2016
  - Small acquisition in 2015: EPIC
- Divestments in 2015
  - Refrigerants in May 2015: net sales of ~€ 50 m in 2014
  - PCC in November 2015: net sales of ~€ 60 m in 2014

## Non-recurring elements
- Restructuring costs
- Impairments related to business not under discontinued operations
- HSE provisions on non-operational sites
- Contingencies / litigations
- Portfolio management-related expenses, gains & losses, e.g. Cytec acquisition
UNDERLYING FINANCIAL & TAX P&L CONSIDERATIONS FOR 2016

Cost of borrowings

- Total underlying financial charges expected at ~€ (350) m (incl. perpetual hybrid bonds)
  - Financial charges from major senior debt (excl. perpetual hybrid bonds)
    - 2016 charges expected at ~€ (150) m
      - Average cost: 2015: 5.2% → 2016: 3.3%
      - EIB loan of € 300 m reimbursed in January 2016
  - Coupons from perpetual hybrid bonds (considered as Dividend & Equity under IFRS)
    - 2016 cash out of € (84) m: Q2 € (57) m / Q4 € (27) m
    - From 2017 onwards € (112) m: Q2 € (84) m / Q4 € (27) m
      - Average cost: 5.1%
  - Other elements ~€(90-100)m
    - Currency swaps & Other debt in consolidated subsidiaries
    - Financial charges RusVinyl\(^{(2)}\): ~€ (25) m

Discounting of pensions and HSE

- P&L: ~€ (100) m (\(\frac{3}{4}\) - pensions, \(\frac{1}{4}\) - HSE)
- Sensitivity to change in discount rates\(^{(1)}\):
  - ~€ (370) m / 50bp
    - Pensions (in OCI)
      - € zone ~€ 140 m
      - USA ~€ 80 m
    - UK ~€ 133 m
    - Others € 10 m
    - HSE (in P&L): €-zone ~€ 10 m

Tax rate

- Underlying tax rate (adjusted for PPA and other factors) expected stable in the low ~30s

---

\(^{(1)}\) Average discount rate on environmental provisions based on 10-year government bonds in EUR, GBP, USD and BRL zones
\(^{(2)}\) Equity accounting, reclassified under underlying accounts as financial interests
## OTHER CONSIDERATIONS FOR 2016

### Discontinued operations

- Indupa chlorovinyls business in Latin America
  - Strategic intent unchanged
  - Disposal process undergoing
  - ~€ (50) m in CTA to be recycled through P&L at exit
- European chlorovinyls until June 30, 2015

### Cash flow elements

- Cash expenses for pensions range of € (180) m - € (200) m
- Capital expenditure of ~€ 950 m
- IWC discipline maintained but growing part of specialty business in portfolio increases needs

### Inovyn JV

- Inovyn JV with INEOS Equity accounting from July 1, 2015
- Exit price of € 335 m agreed between the parties
- Exit expected in H2 2016, subject to finalizing definitive legal agreements and customary regulatory approvals